Palvella Therapeutics (PVLA) Equity Ratio (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Equity Ratio data on file, last reported at 0.88 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.88, up 25.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.88 (up 25.89% YoY), and the FY2025 annual result was 0.47, down 33.78% from the prior year.
• Equity Ratio grew to 0.88 in Q1 2026 per PVLA's latest filing, from 0.47 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.88 in Q1 2026 and troughed at 9.87 in Q4 2023.
• A 5-year average of 0.94 and a median of 0.43 in 2022 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio slumped 1486.82% in 2024, then jumped 126.85% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.98 in 2022, then sank by 904.82% to 9.87 in 2023, then jumped by 107.19% to 0.71 in 2024, then tumbled by 33.78% to 0.47 in 2025, then surged by 87.46% to 0.88 in 2026.
• Business Quant data shows PVLA's Equity Ratio at 0.88 in Q1 2026, 0.47 in Q4 2025, and 0.58 in Q3 2025.